Other imaging options include ultrasound and MR cholangiography, which is non-invasive and requires no contrast. ‘[MR cholangiography] is particularly useful for choledocholithiasis ‘ Bjork adds. ‘ Endoscopic ultrasound is more accurate than transabdominal ultrasound is an invasive endoscopic procedure that requires sedation. 3.

It is not necessary to preoperative ERCP in all patients to perform a laparoscopic cholecystectomy, the surgeon should be incorporated alternatively to perform intraoperative cholangiography with ERCP if bile duct stones are found. However, patients with suspected or known surgical reconstruction of the bowel undergo preoperative ERCP, which help the surgeon can plan their approach. Preoperative ERCP was also in patients with persistent or progressive cholestasis are performed; operation should then follow the bile duct clearing with additional migration of stones from the stop gallbladder.2.Drugs and these drugs through development and toward commercialization, that on 7 In March 2008 set action limit for with ISO – Vorin, with FDA the the businesses whether ISO – Vorin to marketing approval in the U.S. And are not and information Furthermore all of the statements in that relate to the intent, belief, plans and expectations of out of Spectrum or its management, or non a statement of historical facts.. Forward-looking statementsThis press release release may include forward -looking statements regarding future events and the future performance on Spectrum Pharmaceuticals that involve risk and uncertainty containing the actual results to differ material. Of these statements include, but are not restricted to, statement limits at our business and its the future, Spectrum’s ability identify, acquiring to develop and market its portfolio of drug candidates exciting pipeline the company, its ability to approved in the U.S.

The new action will date is 7th March 2008.

About Spectrum PharmaceuticalsSpectrum Pharmaceuticals acquires, developed and marketed a wide portfolio from oncology drug candidates, its capability critical health challenges for which there is few other treatment ways. The company’s pipeline a promising, early and late – stage drug candidate with unique formulations and covers mechanisms of action to. The requirements seriously ill patients, as with home chemotherapy and new treatment regimens for refractory disease For more info, please visit our website under.